LeMaitre Vascular (LMAT) 10-Q 8 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Document Information [Line Items]
Entity Registrant Name	LEMAITRE VASCULAR INC
Entity Central Index Key	0001158895
Trading Symbol	lmat
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		20,178,506
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value per share

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	$ 10,944	$ 11,786
Short-term marketable securities	19,687	20,895
Accounts receivable, net of allowances of $452 at March 31, 2020 and $522 at December 31, 2019	16,630	16,572
Inventory and other deferred costs	40,580	39,527
Prepaid expenses and other current assets	1,881	3,312
Total current assets	89,722	92,092
Property and equipment, net	14,791	14,854
Right-of-use leased assets	14,883	15,208
Goodwill	39,773	39,951
Other intangibles, net	24,059	24,893
Deferred tax assets	1,069	1,084
Other assets	260	259
Total assets	184,557	188,341
Liabilities and stockholders’ equity
Accounts payable	1,381	2,604
Accrued expenses	11,015	14,014
Acquisition-related obligations	2,495	2,476
Lease liabilities - short-term	1,703	1,757
Total current liabilities	16,594	20,851
Lease liabilities - long-term	13,715	13,955
Deferred tax liabilities	1,176	1,179
Other long-term liabilities	4,237	4,215
Total liabilities	35,722	40,200
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 21,702,142 shares at March 31,2020, and 21,678,827 shares at December 31, 2019	217	217
Additional paid-in capital	106,946	105,934
Retained earnings	58,286	57,029
Accumulated other comprehensive loss	(5,525)	(4,007)
Treasury stock, at cost; 1,523,636 shares at March 31, 2020 and 1,522,035 shares at December 31, 2019	(11,089)	(11,032)
Total stockholders’ equity	148,835	148,141
Total liabilities and stockholders’ equity	$ 184,557	$ 188,341

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts receivable, allowances	$ 452	$ 522
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	37,000,000	37,000,000
Common stock, shares issued (in shares)	21,702,142	21,678,827
Treasury stock, at cost (in shares)	1,523,636	1,522,035

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net Sales	$ 30,551	$ 28,479
Cost of sales	10,068	9,015
Gross profit	20,483	19,464
Sales and marketing	7,945	7,845
General and administrative	5,191	4,944
Research and development	2,994	2,240
Total operating expenses	16,130	15,029
Income from operations	4,353	4,435
Other income (expense):
Interest income	105	157
Foreign currency gain (loss)	(178)	(79)
Income before income taxes	4,280	4,513
Provision for income taxes	1,106	1,000
Net income	$ 3,174	$ 3,513
Earnings per share of common stock:
Basic (in dollars per share)	$ 0.16	$ 0.18
Diluted (in dollars per share)	$ 0.16	$ 0.17
Weighted-average shares outstanding:
Basic (in shares)	20,168	19,640
Diluted (in shares)	20,438	20,205
Cash dividends declared per common share (in dollars per share)	$ 0.095	$ 0.085

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net income	$ 3,174	$ 3,513
Other comprehensive income (loss):
Foreign currency translation adjustment, net	(1,208)	(261)
Unrealized gain (loss) on short-term marketable securities	(310)	69
Total other comprehensive income (loss)	(1,518)	(192)
Comprehensive income	$ 1,656	$ 3,321

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018	21,110,224				1,501,511
Balance at Dec. 31, 2018	$ 211	$ 98,442	$ 45,831	$ (3,900)	$ (10,349)	$ 130,235
Net income			3,513			3,513
Other comprehensive income (loss)				(192)		(192)
Issuance of common stock for stock options exercised (in shares)	61,419
Issuance of common stock for stock options exercised	$ 1	478				479
Vested restricted stock units (in shares)	2,026
Vested restricted stock units
Stock-based compensation expense		746				746
Repurchase of common stock at cost (in shares)					926
Repurchase of common stock at cost					$ (21)	(21)
Common stock cash dividend paid/accrued			(1,672)			(1,672)
Balance (in shares) at Mar. 31, 2019	21,173,669				1,502,437
Balance at Mar. 31, 2019	$ 212	99,666	47,672	(4,092)	$ (10,370)	133,088
Balance (in shares) at Dec. 31, 2019	21,678,927				1,522,035
Balance at Dec. 31, 2019	$ 217	105,934	57,029	(4,007)	$ (11,032)	148,141
Net income			3,174			3,174
Other comprehensive income (loss)				(1,518)		(1,518)
Issuance of common stock for stock options exercised (in shares)	19,141
Issuance of common stock for stock options exercised		233				233
Vested restricted stock units (in shares)	4,074
Vested restricted stock units
Stock-based compensation expense		779				779
Repurchase of common stock at cost (in shares)					1,601
Repurchase of common stock at cost					$ (57)	(57)
Common stock cash dividend paid/accrued			(1,917)			(1,917)
Balance (in shares) at Mar. 31, 2020	21,702,142				1,523,636
Balance at Mar. 31, 2020	$ 217	$ 106,946	$ 58,286	$ (5,525)	$ (11,089)	$ 148,835

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net income	$ 3,174	$ 3,513
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,538	1,284
Stock-based compensation	779	746
Fair value adjustment to contingent consideration obligations	64	44
Provision for doubtful accounts	71	121
Provision for inventory write-downs	196	238
Foreign currency transaction loss	208	(54)
Changes in operating assets and liabilities:
Accounts receivable	(368)	30
Inventory and other deferred costs	(1,861)	(2,370)
Prepaid expenses and other assets	659	(261)
Accounts payable and other liabilities	(3,271)	(3,510)
Net cash provided by (used in) operating activities	1,189	(219)
Investing activities
Purchases of property and equipment and other assets	(863)	(802)
Purchases of short-term marketable securities	(2,103)	(10,954)
Sales of short-term marketable securities	3,000
Payments related to acquisitions	(59)
Net cash used in investing activities	(25)	(11,756)
Financing activities
Payments of deferred acquisition consideration		(33)
Proceeds from issuance of common stock	233	457
Purchase of treasury stock	(57)
Common stock cash dividend paid	(1,917)
Net cash provided by (used in) financing activities	(1,741)	424
Effect of exchange rate changes on cash and cash equivalents	(265)	(1)
Net increase (decrease) in cash and cash equivalents	(842)	(11,552)
Cash and cash equivalents at beginning of period	11,786	26,318
Cash and cash equivalents at end of period	$ 10,944	$ 14,766

Note 1 - Organization and Basis

Note 1 - Organization and Basis for Presentation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Description of Business Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 X. not may three March 31, 2020 not December 31, 2019, 10 March 11, 2020. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes to unaudited consolidated financial statements. While the Company has not 19 19 not May 8, 2020, 10 19. Consolidation Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met. We recognize revenue under the provisions of ASU 2014 09, Revenue from Contracts with Customers (Topic 606 606 Step 1: Step 2: Step 3: Step 4: Step 5: Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic 606 not We generally reference customer purchase orders to determine the existence of a contract. Orders that are not one not We recognize revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre Vascular has a present right to receive payment for the goods. Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands): Three months ended March 31, 2020 2019 ($ in thousands) Americas $ 18,336 $ 16,375 Europe, Middle East and Africa 10,350 10,013 Asia/Pacific Rim 1,865 2,091 Total $ 30,551 $ 28,479 We do not no not 30 60 no Customers returning products may 18 twelve 30 not not Recent Accounting Pronouncements In June 2016, No. 2016 13, 326 2016 13” January 1, 2020. not In January 2017, 2017 04, 2” not January 1, 2020. not In August 2018, 2018 13 820 January 1, 2020. not In December 2019, 2019 12 740 740 740. January 1, 2021, not

Note 2 - Income Tax Expense

Note 2 - Income Tax Expense	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	2. As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not not, not We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and may Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense. Our 2020 2019 We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2020, $780,000. 2027. Three months ended March 31, 2020 (in thousands) Unrecognized tax benefits as of December 31, 2019 $ 848 Additions for tax positions of current year - Additions for tax positions of prior years (9 ) Reductions for settlements with taxing authorities (59 ) Reductions for lapses of the applicable statutes of limitations - Unrecognized tax benefits as of March 31, 2020 $ 780 As of March 31, 2020, United States 2016 and forward Foreign 2013 and forward

Note 3 - Inventories and Other

Note 3 - Inventories and Other Deferred Costs	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Inventory and Other Deferred Costs Disclosure [Text Block]	3. Inventories and other deferred costs consist of the following: March 31, 2020 December 31, 2019 (in thousands) Raw materials $ 4,859 $ 5,359 Work-in-process 5,987 6,238 Finished products 24,526 23,032 Other deferred costs 5,208 4,898 Total inventory and other deferred costs $ 40,580 $ 39,527 We had inventory on consignment at customer sites of $ 1.9 March 31, 2020 December 31, 2019. Other deferred costs relate to our RestoreFlow allograft offering and include costs incurred for the preservation of human vascular tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the vascular tissues we preserve are not

Note 4 - Acquisitions and Dives

Note 4 - Acquisitions and Divestitures	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Business Combination Disclosure [Text Block]	4. Our acquisitions are accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. In each case for the acquisitions disclosed below, pro forma information assuming the acquisition had occurred at the beginning of the earliest period presented is not With the exception of Cardial discussed below, our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products and services, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure. The fair market valuations associated with these transactions fall within Level 3 3 13 CardioCel and VascuCel Biologic Patches On October 11, 2019 ( three Under the APA we agreed to pay Admedus a total of up to $15.3 $8.0 $14.2 $0.3 may ● $0.7 15 first ● $0.7 15 third ● $2.0 15 ● $2.5 first 12 $20 $1.2 first 12 $15 ● $2.5 second 12 $30 $1.2 first 12 $22.5 ● $0.5 first 36 60 The following table summarizes the preliminary purchase price allocation: Allocated Fair Value (in thousands) Inventory and other $ 1,343 Intangible assets 8,725 Goodwill 7,344 Purchase price $ 17,412 The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over 15 The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives: Weighted Allocated Fair Value Average Useful Life (in thousands) (in years) Customer relationships $ 5,562 12.0 Intellectual property 2,335 8.0 Non-compete agreement 361 5.0 Tradenames 467 8.0 Total intangible assets $ 8,725 The weighted-average amortization period of the acquired intangible assets was 10.4 Tru-Incise Valve Cutter On July 12, 2019, The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, and customer and supplier information, was $8.0 $6.8 three $0.4 second third $1.2 $1.1 4.19% no may The following table summarizes the preliminary purchase price allocation: Allocated Fair Value (in thousands) Inventory $ 276 Equipmentand supplies 70 Intangible assets 4,844 Goodwill 2,748 Purchase price $ 7,938 The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over 15 The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives: Weighted Allocated Fair Value Average Useful Life (in thousands) (in years) Customer relationships $ 3,945 13.0 Intellectual property 563 7.0 Non-compete agreement 233 5.0 Tradenames 103 7.0 Total intangible assets $ 4,844 The weighted-average amortization period of the acquired intangible assets was 11.8 Cardial On October 22, 2018, The purchase price for the acquired assets, including the land and building, inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was €2.0 $2.3 €1.1 $1.3 €0.5 $0.5 €0.4 $0.4 two twelve eighteen first two not second April 2020, The following table summarizes the purchase price allocation: Allocated Fair Value (in thousands) Inventory € 2,419 Land and building 750 Equipment and supplies 94 Intangible assets 623 Bargain purchase gain (1,946 ) Purchase price € 1,940 The bargain purchase gain was recorded to reflect the excess of the net assets acquired over the purchase price. We recorded deferred taxes on this gain of €0.5 $0.6 €1.4 $1.6 The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives: Allocated Fair Value Weighted Average Useful Life (in thousands) (in years) Customer relationships € 250 16.0 Intellectual property 237 5.0 Non-compete agreement 46 5.0 Tradenames 90 5.0 Total intangible assets € 623 The weighted-average amortization period of the acquired intangible assets was 9.4 Applied Medical Clot Management Business On September 20, 2018, twelve not The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was $14.2 $11.0 $2.0 12 $1.2 24 $3.2 $3.0 3.75% no may The following table summarizes the purchase price allocation: Allocated Fair Value (in thousands) Inventory $ 739 Equipment and supplies 416 Intangible assets 6,527 Goodwill 6,361 Purchase price $ 14,043 The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over 15 The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives: Weighted Allocated Fair Value Average Useful Life (in thousands) (in years) Customer relationships $ 4,475 16.0 Intellectual property 1,316 7.0 Non-compete agreement 530 5.0 Tradenames 206 7.0 Total intangible assets $ 6,527 The weighted-average amortization period of the acquired intangible assets was 13.0 Reddick Divestiture On April 5, 2018, $7.4 two six June 30, 2018 $5.9 Allocated Fair Value (in thousands) Inventory $ 308 Deferred revenue - transition services agreement 1,081 Goodwill 135 Gain on divestiture 5,876 Consideration received $ 7,400 Under the terms of the TSA, we agreed to manufacture the Reddick products for the buyer at prices at or in some cases below our cost. We allocated a portion of the consideration received to the TSA to reflect it at fair value and recorded it as deferred revenue. As the products were sold to the buyer, we amortized a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. The TSA ended by mutual agreement during the quarter ended September 30, 2019

Note 5 - Goodwill and Other Int

Note 5 - Goodwill and Other Intangibles	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	5. Goodwill consists of the following as of March 31, 2020 ( Balance at December 31, 2019 $ 39,951 Additions for acquisitions 59 Effects of currency exchange (237 ) Balance at March 31, 2020 $ 39,773 Other intangible assets consist of the following: March 31, 2020 December 31, 2019 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Value Amortization Value Value Amortization Value (in thousands) Product technology and intellectual property $ 13,502 $ 6,038 $ 7,464 $ 13,502 $ 5,722 $ 7,780 Trademarks, tradenames and licenses 1,807 749 1,058 1,807 702 1,105 Customer relationships 18,215 3,700 14,515 18,215 3,364 14,851 Other intangible assets 1,663 641 1,022 1,725 568 1,157 Total identifiable intangible assets $ 35,187 $ 11,128 $ 24,059 $ 35,249 $ 10,356 $ 24,893 These intangible assets are being amortized over their useful lives ranging from 2 16 March 31, 2020 10.2 Three months ended March 31, 2020 2019 (in thousands) Amortization expense $ 834 $ 555 We estimate that amortization expense for the remainder of 2020 five Year ended December 31, 2020 2021 2022 2023 2024 2025 (in thousands) Amortization expense $ 2,391 $ 2,956 $ 2,751 $ 2,677 $ 2,478 $ 2,253

Note 6 - Leases

Note 6 - Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. We conduct the majority of our operations in leased facilities, all of which are accounted for as operating leases, as they do not three 27,098 27,289 15,642 fourth 12,878 October 2019 26,447 four four five December 2030. October 2019 2,258 16,470 3,630 2019, August 2023. two five five February 2023. September May, twelve None no no no March 31, 2020. We also lease automobiles under operating leases in the U.S. as well as certain of our international subsidiaries. The terms of these leases are generally three We account for leases under the provisions of ASU No. 2016 02, Leases (Topic 842 2018 11, Leases (Topic 842 Our most significant judgment involved in determining the amounts to initially record as lease liabilities and right-of-use assets upon initial adoption of this standard and for leases entered into subsequently was the selection of a discount rate; because we have no no 5.25%. Additional information with respect to our leases is as follows: Three Months Ended March 31, 2020 2019 Lease cost Operating lease cost 474 422 Short-term lease cost 13 68 Total lease cost $ 487 $ 490 Other information Cash paid for amounts included in the measurement of operating lease liabilities $ 591 $ 514 Right-of-use assets obtained in exchange for new operating lease liabilities $ 149 $ 217 Weighted average remaining lease term in years - operating leases 8.6 4.2 Weighted average discount rate - operating leases 5.25 % 5.25 % At March 31, 2020, one Remainder of 2020 $ 1,922 Year ending December 31, 2021 2,354 2022 1,986 2023 1,685 2024 1,571 Thereafter 10,288 Adjustment to net present value as of March 31, 2020 (4,388 ) Minimum noncancelable lease liability $ 15,418

Note 7 - Accrued Expenses and O

Note 7 - Accrued Expenses and Other Long-term Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]	7. Accrued expenses consist of the following: March 31, 2020 December 31, 2019 (in thousands) Compensation and related taxes $ 4,899 $ 8,550 Income and other taxes 1,073 1,003 Professional fees 236 40 Other 4,807 4,421 Total $ 11,015 $ 14,014 Other long-term liabilities consist of the following: March 31, 2020 December 31, 2019 (in thousands) Aquisition-related liabilities $ 3,306 $ 3,268 Income taxes 771 781 Other 160 166 Total $ 4,237 $ 4,215

Note 8 - Segment and Enterprise

Note 8 - Segment and Enterprise-wide Disclosures	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	8. Under Accounting Standards Codification Topic 280, Segment Reporting one No Most of our revenues are generated in the United States, Germany, and other European countries as well as in Canada, Japan and China. Substantially all of our assets are located in the United States, Australia and France. Net sales to unaffiliated customers by country were as follows: Three months ended March 31, 2020 2019 (in thousands) United States $ 17,000 $ 14,758 Germany 3,294 3,080 Other countries 10,257 10,641 Net Sales $ 30,551 $ 28,479

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9. Our Third Amended and Restated 2006 Three months ended March 31, 2020 2019 (in thousands) Stock option awards $ 500 $ 447 Restricted stock units 279 299 Total share-based compensation $ 779 $ 746 Stock-based compensation is included in our statements of operations as follows: Three months ended March 31, 2020 2019 (in thousands) Cost of sales $ 81 $ 82 Sales and marketing 159 158 General and administrative 454 419 Research and development 85 87 Total stock-based compensation $ 779 $ 746 We did not three March 31, 2020 2019. March 31, 2020, 2,100 23,000 63,000 three March 31, 2020 2019,

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	10. The computation of basic and diluted net income per share was as follows: Three months ended March 31, 2020 2019 (in thousands, except per share data) Basic: Net income available for common stockholders $ 3,174 $ 3,513 Weighted average shares outstanding 20,168 19,640 Basic earnings per share $ 0.16 $ 0.18 Diluted: Net income available for common stockholders $ 3,174 $ 3,513 Weighted-average shares outstanding 20,168 19,640 Common stock equivalents, if dilutive 270 565 Shares used in computing diluted earnings per common share 20,438 20,205 Diluted earnings per share $ 0.16 $ 0.17 Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive 468 542

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Share Repurchase Program On February 14, 2019, $10.0 February 13, 2020, February 14, 2021. may not Dividends In February 2011, Record Date Payment Date Per Share Amount Dividend Payment (in thousands) Fiscal Year 2020 March 3, 2020 March 19, 2020 $ 0.095 $ 1,917 Fiscal Year 2019 March 22, 2019 April 5, 2019 $ 0.085 $ 1,672 May 22, 2019 June 5, 2019 $ 0.085 $ 1,672 August 21, 2019 September 5, 2019 $ 0.085 $ 1,691 November 20, 2019 December 5, 2019 $ 0.085 $ 1,701 On April 28, 2020, $0.095 June 4, 2020 May 20, 2020 $1.9

Note 12 - Supplemental Cash Flo

Note 12 - Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	12. plemental Cash Flow Information Three Months Ended March 31, 2020 2019 (in thousands) Cash paid for income taxes, net $ 526 $ 2,173

Note 13 - Fair Value Measuremen

Note 13 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	13. The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one three • Level 1 • Level 2 1, not • Level 3 no Level 1 March 31, 2020 We had no 2 March 31, 2020. As discussed in Note 4, 3 2019, $7.8 $0.3 November 2019; $2.0 $0.5 $5.0 first 12 24 $2.3 3 Threee months ended March 31, 2020 2019 (in thousands) Beginning balance $ 1,765 $ 72 Additions - - Payments - (33 ) Change in fair value included in earnings 28 (13 ) Ending balance $ 1,793 $ 26

Note 14 - Accumulated Other Com

Note 14 - Accumulated Other Comprehensive Loss	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	14. Changes to our accumulated other comprehensive loss for the three March 31, 2020 2019 Three months ended March 31, 2020 2019 (in thousands) Beginning balance $ (4,007 ) $ (3,900 ) Other comprehensive income (loss) before reclassifications (1,518 ) (192 ) Amounts reclassified from accumulated other comprehensive loss - - Ending Balance $ (5,525 ) $ (4,092 )

Note 15 - Subsequent Event and

Note 15 - Subsequent Event and Other Information	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	15. Asset s Held for Sale During the three March 31, 2020, A$2.7 $1.7 September 2020, no A$1.9 $1.2 March 31, 2020,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 X. not may three March 31, 2020 not December 31, 2019, 10 March 11, 2020. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes to unaudited consolidated financial statements. While the Company has not 19 19 not May 8, 2020, 10 19.
Consolidation, Policy [Policy Text Block]	Consolidation Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met. We recognize revenue under the provisions of ASU 2014 09, Revenue from Contracts with Customers (Topic 606 606 Step 1: Step 2: Step 3: Step 4: Step 5: Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic 606 not We generally reference customer purchase orders to determine the existence of a contract. Orders that are not one not We recognize revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre Vascular has a present right to receive payment for the goods. Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands): Three months ended March 31, 2020 2019 ($ in thousands) Americas $ 18,336 $ 16,375 Europe, Middle East and Africa 10,350 10,013 Asia/Pacific Rim 1,865 2,091 Total $ 30,551 $ 28,479 We do not no not 30 60 no Customers returning products may 18 twelve 30 not not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2016, No. 2016 13, 326 2016 13” January 1, 2020. not In January 2017, 2017 04, 2” not January 1, 2020. not In August 2018, 2018 13 820 January 1, 2020. not In December 2019, 2019 12 740 740 740. January 1, 2021, not

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis for Presentation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended March 31, 2020 2019 ($ in thousands) Americas $ 18,336 $ 16,375 Europe, Middle East and Africa 10,350 10,013 Asia/Pacific Rim 1,865 2,091 Total $ 30,551 $ 28,479

Note 2 - Income Tax Expense (Ta

Note 2 - Income Tax Expense (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Three months ended March 31, 2020 (in thousands) Unrecognized tax benefits as of December 31, 2019 $ 848 Additions for tax positions of current year - Additions for tax positions of prior years (9 ) Reductions for settlements with taxing authorities (59 ) Reductions for lapses of the applicable statutes of limitations - Unrecognized tax benefits as of March 31, 2020 $ 780
Summary of Income Tax Examinations [Table Text Block]	United States 2016 and forward Foreign 2013 and forward

Note 3 - Inventories and Othe_2

Note 3 - Inventories and Other Deferred Costs (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2020 December 31, 2019 (in thousands) Raw materials $ 4,859 $ 5,359 Work-in-process 5,987 6,238 Finished products 24,526 23,032 Other deferred costs 5,208 4,898 Total inventory and other deferred costs $ 40,580 $ 39,527

Note 4 - Acquisitions and Div_2

Note 4 - Acquisitions and Divestitures (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Allocated Fair Value (in thousands) Inventory and other $ 1,343 Intangible assets 8,725 Goodwill 7,344 Purchase price $ 17,412 Allocated Fair Value (in thousands) Inventory $ 276 Equipmentand supplies 70 Intangible assets 4,844 Goodwill 2,748 Purchase price $ 7,938 Allocated Fair Value (in thousands) Inventory € 2,419 Land and building 750 Equipment and supplies 94 Intangible assets 623 Bargain purchase gain (1,946 ) Purchase price € 1,940 Allocated Fair Value (in thousands) Inventory $ 739 Equipment and supplies 416 Intangible assets 6,527 Goodwill 6,361 Purchase price $ 14,043
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	Weighted Allocated Fair Value Average Useful Life (in thousands) (in years) Customer relationships $ 5,562 12.0 Intellectual property 2,335 8.0 Non-compete agreement 361 5.0 Tradenames 467 8.0 Total intangible assets $ 8,725 Weighted Allocated Fair Value Average Useful Life (in thousands) (in years) Customer relationships $ 3,945 13.0 Intellectual property 563 7.0 Non-compete agreement 233 5.0 Tradenames 103 7.0 Total intangible assets $ 4,844 Allocated Fair Value Weighted Average Useful Life (in thousands) (in years) Customer relationships € 250 16.0 Intellectual property 237 5.0 Non-compete agreement 46 5.0 Tradenames 90 5.0 Total intangible assets € 623 Weighted Allocated Fair Value Average Useful Life (in thousands) (in years) Customer relationships $ 4,475 16.0 Intellectual property 1,316 7.0 Non-compete agreement 530 5.0 Tradenames 206 7.0 Total intangible assets $ 6,527
Disposal Groups, Including Discontinued Operations [Table Text Block]	Allocated Fair Value (in thousands) Inventory $ 308 Deferred revenue - transition services agreement 1,081 Goodwill 135 Gain on divestiture 5,876 Consideration received $ 7,400

Note 5 - Goodwill and Other I_2

Note 5 - Goodwill and Other Intangibles (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Goodwill [Table Text Block]	Balance at December 31, 2019 $ 39,951 Additions for acquisitions 59 Effects of currency exchange (237 ) Balance at March 31, 2020 $ 39,773
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2020 December 31, 2019 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Value Amortization Value Value Amortization Value (in thousands) Product technology and intellectual property $ 13,502 $ 6,038 $ 7,464 $ 13,502 $ 5,722 $ 7,780 Trademarks, tradenames and licenses 1,807 749 1,058 1,807 702 1,105 Customer relationships 18,215 3,700 14,515 18,215 3,364 14,851 Other intangible assets 1,663 641 1,022 1,725 568 1,157 Total identifiable intangible assets $ 35,187 $ 11,128 $ 24,059 $ 35,249 $ 10,356 $ 24,893
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Three months ended March 31, 2020 2019 (in thousands) Amortization expense $ 834 $ 555
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ended December 31, 2020 2021 2022 2023 2024 2025 (in thousands) Amortization expense $ 2,391 $ 2,956 $ 2,751 $ 2,677 $ 2,478 $ 2,253

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended March 31, 2020 2019 Lease cost Operating lease cost 474 422 Short-term lease cost 13 68 Total lease cost $ 487 $ 490 Other information Cash paid for amounts included in the measurement of operating lease liabilities $ 591 $ 514 Right-of-use assets obtained in exchange for new operating lease liabilities $ 149 $ 217 Weighted average remaining lease term in years - operating leases 8.6 4.2 Weighted average discount rate - operating leases 5.25 % 5.25 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Remainder of 2020 $ 1,922 Year ending December 31, 2021 2,354 2022 1,986 2023 1,685 2024 1,571 Thereafter 10,288 Adjustment to net present value as of March 31, 2020 (4,388 ) Minimum noncancelable lease liability $ 15,418

Note 7 - Accrued Expenses and_2

Note 7 - Accrued Expenses and Other Long-term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2020 December 31, 2019 (in thousands) Compensation and related taxes $ 4,899 $ 8,550 Income and other taxes 1,073 1,003 Professional fees 236 40 Other 4,807 4,421 Total $ 11,015 $ 14,014
Other Noncurrent Liabilities [Table Text Block]	March 31, 2020 December 31, 2019 (in thousands) Aquisition-related liabilities $ 3,306 $ 3,268 Income taxes 771 781 Other 160 166 Total $ 4,237 $ 4,215

Note 8 - Segment and Enterpri_2

Note 8 - Segment and Enterprise-wide Disclosures (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three months ended March 31, 2020 2019 (in thousands) United States $ 17,000 $ 14,758 Germany 3,294 3,080 Other countries 10,257 10,641 Net Sales $ 30,551 $ 28,479

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Cost by Plan [Table Text Block]	Three months ended March 31, 2020 2019 (in thousands) Stock option awards $ 500 $ 447 Restricted stock units 279 299 Total share-based compensation $ 779 $ 746
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended March 31, 2020 2019 (in thousands) Cost of sales $ 81 $ 82 Sales and marketing 159 158 General and administrative 454 419 Research and development 85 87 Total stock-based compensation $ 779 $ 746

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended March 31, 2020 2019 (in thousands, except per share data) Basic: Net income available for common stockholders $ 3,174 $ 3,513 Weighted average shares outstanding 20,168 19,640 Basic earnings per share $ 0.16 $ 0.18 Diluted: Net income available for common stockholders $ 3,174 $ 3,513 Weighted-average shares outstanding 20,168 19,640 Common stock equivalents, if dilutive 270 565 Shares used in computing diluted earnings per common share 20,438 20,205 Diluted earnings per share $ 0.16 $ 0.17 Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive 468 542

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Dividends Payable [Table Text Block]	Record Date Payment Date Per Share Amount Dividend Payment (in thousands) Fiscal Year 2020 March 3, 2020 March 19, 2020 $ 0.095 $ 1,917 Fiscal Year 2019 March 22, 2019 April 5, 2019 $ 0.085 $ 1,672 May 22, 2019 June 5, 2019 $ 0.085 $ 1,672 August 21, 2019 September 5, 2019 $ 0.085 $ 1,691 November 20, 2019 December 5, 2019 $ 0.085 $ 1,701

Note 12 - Supplemental Cash F_2

Note 12 - Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Three Months Ended March 31, 2020 2019 (in thousands) Cash paid for income taxes, net $ 526 $ 2,173

Note 13 - Fair Value Measurem_2

Note 13 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Threee months ended March 31, 2020 2019 (in thousands) Beginning balance $ 1,765 $ 72 Additions - - Payments - (33 ) Change in fair value included in earnings 28 (13 ) Ending balance $ 1,793 $ 26

Note 14 - Accumulated Other C_2

Note 14 - Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Three months ended March 31, 2020 2019 (in thousands) Beginning balance $ (4,007 ) $ (3,900 ) Other comprehensive income (loss) before reclassifications (1,518 ) (192 ) Amounts reclassified from accumulated other comprehensive loss - - Ending Balance $ (5,525 ) $ (4,092 )

Note 1 - Organization and Bas_3

Note 1 - Organization and Basis for Presentation (Details Textual)	3 Months Ended
	Mar. 31, 2020
Number of Operating Segments	1
Minimum [Member]
Period of Payments Received from Customers (Day)	30 days
Maximum [Member]
Period of Payments Received from Customers (Day)	60 days

Note 1 - Organization and Bas_4

Note 1 - Organization and Basis for Presentation - Disaggregation of Revenue by Major Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 30,551	$ 28,479
Americas [Member]
Revenue	18,336	16,375
EMEA [Member]
Revenue	10,350	10,013
Asia Pacific [Member]
Revenue	$ 1,865	$ 2,091

Note 2 - Income Tax Expense (De

Note 2 - Income Tax Expense (Details Textual) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Unrecognized Tax Benefits, Ending Balance	$ 780,000	$ 848,000

Note 2 - Income Tax Expense - R

Note 2 - Income Tax Expense - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Unrecognized tax benefits as of December 31, 2019	$ 848,000
Additions for tax positions of current year
Additions for tax positions of prior years	(9,000)
Reductions for settlements with taxing authorities	(59,000)
Reductions for lapses of the applicable statutes of limitations
Unrecognized tax benefits as of March 31, 2020	$ 780,000

Note 2 - Income Tax Expense - S

Note 2 - Income Tax Expense - Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions (Details)	3 Months Ended
	Mar. 31, 2020
Domestic Tax Authority [Member]
Income tax year under examination	2016 2017 2018 2019 2020
Foreign Tax Authority [Member]
Income tax year under examination	2013 2014 2015 2016 2017 2018 2019 2020

Note 3 - Inventories and Othe_3

Note 3 - Inventories and Other Deferred Costs (Details Textual) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross	$ 1.9	$ 1.9

Note 3 - Inventories and Othe_4

Note 3 - Inventories and Other Deferred Costs - Summary of Inventories and Other Deferred Costs (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Raw materials	$ 4,859	$ 5,359
Work-in-process	5,987	6,238
Finished products	24,526	23,032
Other deferred costs	5,208	4,898
Total inventory and other deferred costs	$ 40,580	$ 39,527

Note 4 - Acquisitions and Div_3

Note 4 - Acquisitions and Divestitures (Details Textual) € in Millions, $ in Millions	Oct. 11, 2019USD ($)	Jul. 12, 2019USD ($)	Oct. 22, 2018USD ($)	Oct. 22, 2018EUR (€)	Sep. 20, 2018USD ($)	Apr. 05, 2018USD ($)	Mar. 31, 2020	Jun. 30, 2018USD ($)	Oct. 22, 2018EUR (€)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)							10 years 73 days
Reddick Divestiture [Member]
Proceeds from Sale of Productive Assets, Total						$ 7.4
Long-term Purchase Commitment, Period (Year)						2 years
Gain (Loss) on Disposition of Assets for Financial Service Operations, Total								$ 5.9
CardioCel and VascuCel Biologic Patches [Member]
Payments to Acquire Businesses, Gross	$ 14.2
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)	10 years 146 days
CardioCel and VascuCel Biologic Patches [Member] | Achieving Audited Financial Statements of Acquired Business [Member]
Payments to Acquire Businesses, Gross	$ 0.3
CardioCel and VascuCel Biologic Patches [Member] | First Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	0.7
CardioCel and VascuCel Biologic Patches [Member] | Second Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	0.7
CardioCel and VascuCel Biologic Patches [Member] | Third Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	2
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Twenty Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	2.5
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Fifteen Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	1.2
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Thirty Million in the Second Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	2.5
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Twenty-Two and a Half Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	1.2
CardioCel and VascuCel Biologic Patches [Member] | Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	0.5
CardioCel and VascuCel Biologic Patches [Member] | Technology Licenses [Member]
Business Combination, Consideration Transferred, Total	8
CardioCel and VascuCel Biologic Patches [Member] | Maximum [Member] | Biological Patch Business Assets [Member]
Business Combination, Consideration Transferred, Total	$ 15.3
Tru-Incise Valve Cutter [Member]
Business Combination, Consideration Transferred, Total		$ 8
Payments to Acquire Businesses, Gross		$ 6.8
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)		11 years 292 days
Business Combination, Deferred Purchase Consideration, Installment Payment		$ 0.4
Business Combination, Deferred Purchase Consideration		1.2
Acquisition Date Fair Value		$ 1.1
Business Combination ,Fair Value Inputs, Discount Rate		4.19%
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period (Year)		15 years
Cardial [Member]
Business Combination, Consideration Transferred, Total			$ 2.3	€ 2
Payments to Acquire Businesses, Gross			$ 1.3	€ 1.1
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)			9 years 146 days	9 years 146 days
Business Combination, Deferred Purchase Consideration			$ 0.4						€ 0.4
Business Combination, Consideration Transferred, Liabilities Incurred			0.5	€ 0.5
Deferred Tax Assets, Business Combinations			0.6						€ 0.5
Business Combination, Bargain Purchase, Gain Recognized, Amount			$ 1.6	€ 1.4
Applied Medical [Member]
Business Combination, Consideration Transferred, Total					$ 14.2
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)					13 years
Acquisition Date Fair Value					$ 3
Business Combination ,Fair Value Inputs, Discount Rate					3.75%
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period (Year)					15 years
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Deferred Costs					$ 3.2
Applied Medical [Member] | Closing Date [Member]
Business Combination, Consideration Transferred, Total					11
Applied Medical [Member] | 12 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					2
Applied Medical [Member] | 24 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					$ 1.2
Balloon Supply Agreement [Member] | Reddick Divestiture [Member]
Long-term Purchase Commitment, Period (Year)						6 years

Note 4 - Acquisitions and Div_4

Note 4 - Acquisitions and Divestitures - Assets Acquired and Liabilities Assumed (Details) € in Thousands, $ in Thousands	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Oct. 11, 2019USD ($)	Jul. 12, 2019USD ($)	Oct. 22, 2018EUR (€)	Sep. 20, 2018USD ($)
Goodwill	$ 39,773	$ 39,951
Goodwill	$ 39,773	$ 39,951
CardioCel and VascuCel Biologic Patches [Member]
Inventory and other			$ 1,343
Intangible assets			8,725
Goodwill			7,344
Purchase price			17,412
Intangible assets			8,725
Goodwill			$ 7,344
Tru-Incise Valve Cutter [Member]
Intangible assets				$ 4,844
Goodwill				2,748
Purchase price				7,938
Inventory				276
Equipmentand supplies				70
Intangible assets				4,844
Goodwill				$ 2,748
Cardial [Member]
Intangible assets | €					€ 623
Purchase price | €					1,940
Inventory | €					2,419
Equipmentand supplies | €					94
Intangible assets | €					623
Land and building | €					750
Bargain purchase gain | €					€ (1,946)
Applied Medical [Member]
Intangible assets						$ 6,527
Goodwill						6,361
Purchase price						14,043
Inventory						739
Equipmentand supplies						416
Intangible assets						6,527
Goodwill						$ 6,361

Note 4 - Acquisitions and Div_5

Note 4 - Acquisitions and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Details) € in Thousands, $ in Thousands	Oct. 11, 2019USD ($)	Jul. 12, 2019USD ($)	Oct. 22, 2018EUR (€)	Sep. 20, 2018USD ($)	Mar. 31, 2020
Weighted Average Useful Life (Year)					10 years 73 days
CardioCel and VascuCel Biologic Patches [Member]
Intangible assets	$ 8,725
Weighted Average Useful Life (Year)	10 years 146 days
CardioCel and VascuCel Biologic Patches [Member] | Customer Relationships [Member]
Intangible assets	$ 5,562
Weighted Average Useful Life (Year)	12 years
CardioCel and VascuCel Biologic Patches [Member] | Intellectual Property [Member]
Intangible assets	$ 2,335
Weighted Average Useful Life (Year)	8 years
CardioCel and VascuCel Biologic Patches [Member] | Noncompete Agreements [Member]
Intangible assets	$ 361
Weighted Average Useful Life (Year)	5 years
CardioCel and VascuCel Biologic Patches [Member] | Trade Names [Member]
Intangible assets	$ 467
Weighted Average Useful Life (Year)	8 years
Tru-Incise Valve Cutter [Member]
Intangible assets		$ 4,844
Weighted Average Useful Life (Year)		11 years 292 days
Tru-Incise Valve Cutter [Member] | Customer Relationships [Member]
Intangible assets		$ 3,945
Weighted Average Useful Life (Year)		13 years
Tru-Incise Valve Cutter [Member] | Intellectual Property [Member]
Intangible assets		$ 563
Weighted Average Useful Life (Year)		7 years
Tru-Incise Valve Cutter [Member] | Noncompete Agreements [Member]
Intangible assets		$ 233
Weighted Average Useful Life (Year)		5 years
Tru-Incise Valve Cutter [Member] | Trade Names [Member]
Intangible assets		$ 103
Weighted Average Useful Life (Year)		7 years
Cardial [Member]
Intangible assets | €			€ 623
Weighted Average Useful Life (Year)			9 years 146 days
Cardial [Member] | Customer Relationships [Member]
Intangible assets | €			€ 250
Weighted Average Useful Life (Year)			16 years
Cardial [Member] | Intellectual Property [Member]
Intangible assets | €			€ 237
Weighted Average Useful Life (Year)			5 years
Cardial [Member] | Noncompete Agreements [Member]
Intangible assets | €			€ 46
Weighted Average Useful Life (Year)			5 years
Cardial [Member] | Trade Names [Member]
Intangible assets | €			€ 90
Weighted Average Useful Life (Year)			5 years
Applied Medical [Member]
Intangible assets				$ 6,527
Weighted Average Useful Life (Year)				13 years
Applied Medical [Member] | Customer Relationships [Member]
Intangible assets				$ 4,475
Weighted Average Useful Life (Year)				16 years
Applied Medical [Member] | Intellectual Property [Member]
Intangible assets				$ 1,316
Weighted Average Useful Life (Year)				7 years
Applied Medical [Member] | Noncompete Agreements [Member]
Intangible assets				$ 530
Weighted Average Useful Life (Year)				5 years
Applied Medical [Member] | Trade Names [Member]
Intangible assets				$ 206
Weighted Average Useful Life (Year)				7 years

Note 4 - Acquisitions and Div_6

Note 4 - Acquisitions and Divestitures - Asset Purchase Agreement (Details) - Reddick Divestiture [Member] $ in Thousands	Apr. 05, 2018USD ($)
Inventory	$ 308
Deferred revenue - transition services agreement	1,081
Goodwill	135
Gain on divestiture	5,876
Consideration received	$ 7,400

Note 5 - Goodwill and Other I_3

Note 5 - Goodwill and Other Intangibles (Details Textual)	3 Months Ended
	Mar. 31, 2020
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)	10 years 73 days
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	16 years

Note 5 - Goodwill and Other I_4

Note 5 - Goodwill and Other Intangibles - Schedule of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Balance at December 31, 2019	$ 39,951
Additions for acquisitions	59
Effects of currency exchange	(237)
Balance at March 31, 2020	$ 39,773

Note 5 - Goodwill and Other I_5

Note 5 - Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Gross carrying value	$ 35,187	$ 35,249
Accumulated amortization	11,128	10,356
Net carrying value	24,059	24,893
Product Technology and Intellectual Property [Member]
Gross carrying value	13,502	13,502
Accumulated amortization	6,038	5,722
Net carrying value	7,464	7,780
Trademarks, Tradenames and Licenses [Member]
Gross carrying value	1,807	1,807
Accumulated amortization	749	702
Net carrying value	1,058	1,105
Customer Relationships [Member]
Gross carrying value	18,215	18,215
Accumulated amortization	3,700	3,364
Net carrying value	14,515	14,851
Other Intangible Assets [Member]
Gross carrying value	1,663	1,725
Accumulated amortization	641	568
Net carrying value	$ 1,022	$ 1,157

Note 5 - Goodwill and Other I_6

Note 5 - Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Amortization expense	$ 834	$ 555

Note 5 - Goodwill and Other I_7

Note 5 - Goodwill and Other Intangibles - Estimated Amortization Expense for Each of Five Succeeding Fiscal Years (Details) $ in Thousands	Mar. 31, 2020USD ($)
2020	$ 2,391
2021	2,956
2022	2,751
2023	2,677
2024	2,478
2025	$ 2,253

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual) $ in Thousands	Mar. 31, 2020USD ($)ft²a
Finance Lease, Right-of-Use Asset | $	$ 0
Lessee, Operating Lease, Discount Rate	5.25%
Leased Automobiles [Member]
Lessee, Operating Lease, Term of Contract (Year)	3 years
GERMANY
Lessee, Operating Lease, Renewal Term (Year)	5 years
CANADA
Lessee, Operating Lease, Renewal Term (Year)	5 years
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility One [Member]
Area of Real Estate Property (Square Foot)	27,098
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Two [Member]
Area of Real Estate Property (Square Foot)	27,289
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Three [Member]
Area of Real Estate Property (Square Foot)	15,642
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Four [Member] | Massachusetts [Member]
Area of Real Estate Property (Square Foot)	12,878
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Five [Member] | Massachusetts [Member]
Area of Real Estate Property (Square Foot) | a	26,447
United Kingdom Sales and Distribution Business [Member] | Hereford, England [Member]
Area of Real Estate Property (Square Foot) | a	2,258
International Operations Headquarter Facility [Member] | GERMANY
Area of Real Estate Property (Square Foot)	16,470
Additional Area of Real Estate Property Added (Square Foot)	3,630

Note 6 - Leases - Additional Le

Note 6 - Leases - Additional Lease Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating lease cost	$ 474	$ 422
Short-term lease cost	13	68
Total lease cost	487	490
Cash paid for amounts included in the measurement of operating lease liabilities	591	514
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 149	$ 217
Weighted average remaining lease term in years - operating leases (Year)	8 years 219 days	4 years 73 days
Weighted average discount rate - operating leases	5.25%	5.25%

Note 6 - Leases - Minimum Renta

Note 6 - Leases - Minimum Rental Commitments (Details) $ in Thousands	Mar. 31, 2020USD ($)
Remainder of 2020	$ 1,922
2021	2,354
2022	1,986
2023	1,685
2024	1,571
Thereafter	10,288
Adjustment to net present value as of March 31, 2020	(4,388)
Minimum noncancelable lease liability	$ 15,418

Note 7 - Accrued Expenses and_3

Note 7 - Accrued Expenses and Other Long-term Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Compensation and related taxes	$ 4,899	$ 8,550
Income and other taxes	1,073	1,003
Professional fees	236	40
Other	4,807	4,421
Total	$ 11,015	$ 14,014

Note 7 - Accrued Expenses and_4

Note 7 - Accrued Expenses and Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Aquisition-related liabilities	$ 3,306	$ 3,268
Income taxes	771	781
Other	160	166
Total	$ 4,237	$ 4,215

Note 8 - Segment and Enterpri_3

Note 8 - Segment and Enterprise-wide Disclosures (Details Textual)	3 Months Ended
	Mar. 31, 2020
Number of Operating Segments	1

Note 8 - Segment and Enterpri_4

Note 8 - Segment and Enterprise-wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net Sales	$ 30,551	$ 28,479
UNITED STATES
Net Sales	17,000	14,758
GERMANY
Net Sales	3,294	3,080
Other Countries [Member]
Net Sales	$ 10,257	$ 10,641

Note 9 - Share-based Compensa_3

Note 9 - Share-based Compensation (Details Textual) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	0	0
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total (in shares)	23,000	63,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	2,100

Note 9 - Share-based Compensa_4

Note 9 - Share-based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation	$ 779	$ 746
Share-based Payment Arrangement, Option [Member]
Stock-based compensation	500	447
Restricted Stock Units (RSUs) [Member]
Stock-based compensation	$ 279	$ 299

Note 9 - Share-based Compensa_5

Note 9 - Share-based Compensation - Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total stock-based compensation	$ 779	$ 746
Cost of Sales [Member]
Total stock-based compensation	81	82
Selling and Marketing Expense [Member]
Total stock-based compensation	159	158
General and Administrative Expense [Member]
Total stock-based compensation	454	419
Research and Development Expense [Member]
Total stock-based compensation	$ 85	$ 87

Note 10 - Net Income per Shar_2

Note 10 - Net Income per Share - Computation of Basic and Diluted Net Income per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic:
Net income	$ 3,174	$ 3,513
Weighted average shares outstanding (in shares)	20,168	19,640
Basic earnings per share (in dollars per share)	$ 0.16	$ 0.18
Diluted:
Net income	$ 3,174	$ 3,513
Weighted average shares outstanding (in shares)	20,168	19,640
Common stock equivalents, if dilutive (in shares)	270	565
Shares used in computing diluted earnings per common share (in shares)	20,438	20,205
Diluted earnings per share (in dollars per share)	$ 0.16	$ 0.17
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive (in shares)	468	542

Note 11 - Stockholders' Equit_2

Note 11 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	Apr. 28, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Feb. 14, 2019
Common Stock, Dividends, Per Share, Declared (in dollars per share)		$ 0.095	$ 0.085
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.095
Dividends Payable, Date to be Paid	Jun. 4, 2020
Dividends Payable, Date of Record	May 20, 2020
Dividends Payable	$ 1.9
Stock Repurchase Program [Member] | Common Stock [Member]
Stock Repurchase Program, Authorized Amount					$ 10
Treasury Stock, Shares, Acquired (in shares)				0

Note 11 - Stockholders' Equit_3

Note 11 - Stockholders' Equity - Dividend Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Per share amount (in dollars per share)	$ 0.095	$ 0.085
Quarterly Dividends 1 [Member]
Record date	Mar. 3, 2020
Payment date	Mar. 19, 2020
Per share amount (in dollars per share)	$ 0.095
Dividend payment	$ 1,917
Quarterly Dividends 2 [Member]
Record date	Mar. 22, 2019
Payment date	Apr. 5, 2019
Per share amount (in dollars per share)	$ 0.085
Dividend payment	$ 1,672
Quarterly Dividends 3 [Member]
Record date	May 22, 2019
Payment date	Jun. 5, 2019
Per share amount (in dollars per share)	$ 0.085
Dividend payment	$ 1,672
Quarterly Dividends 4 [Member]
Record date	Aug. 21, 2019
Payment date	Sep. 5, 2019
Per share amount (in dollars per share)	$ 0.085
Dividend payment	$ 1,691
Quarterly Dividends 5 [Member]
Record date	Nov. 20, 2019
Payment date	Dec. 5, 2019
Per share amount (in dollars per share)	$ 0.085
Dividend payment	$ 1,701

Note 12 - Supplemental Cash F_3

Note 12 - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash paid for income taxes, net	$ 526	$ 2,173

Note 13 - Fair Value Measurem_3

Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Oct. 11, 2019
CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 7,800
CardioCel and VascuCel Biologic Patches [Member] | Audited Carve-Out Financial Statements of the Acquired Business [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		300
CardioCel and VascuCel Biologic Patches [Member] | Third Holdback [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		2,000
Business Combination, Contingent Consideration, Liability, Total			$ 2,000
CardioCel and VascuCel Biologic Patches [Member] | Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		500
Business Combination, Contingent Consideration, Liability, Total			500
CardioCel and VascuCel Biologic Patches [Member] | Achievement of Specified Levels of Revenues [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 5,000
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Assets, Fair Value Disclosure	$ 0
Fair Value, Inputs, Level 3 [Member] | CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Contingent Consideration, Liability, Total			$ 2,300

Note 13 - Fair Value Measurem_4

Note 13 - Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Beginning balance	$ 1,765	$ 72
Additions
Payments		(33)
Change in fair value included in earnings	28	(13)
Ending balance	$ 1,793	$ 26

Note 14 - Accumulated Other C_3

Note 14 - Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 148,141	$ 130,235
Balance	148,835	133,088
AOCI Attributable to Parent [Member]
Balance	(4,007)	(3,900)
Other comprehensive income (loss) before reclassifications	(1,518)	(192)
Amounts reclassified from accumulated other comprehensive loss
Balance	$ (5,525)	$ (4,092)

Note 15 - Subsequent Event an_2

Note 15 - Subsequent Event and Other Information (Details Textual) - Mar. 31, 2020 - Land and Building Located in North Melbourne, Australia [Member] $ in Millions, $ in Millions	USD ($)	AUD ($)
Property, Plant and Equipment, Disposals	$ 1.7	$ 2.7
Property, Plant and Equipment, Gross, Ending Balance	$ 1.2	$ 1.9